Comparative Pharmacology
Head-to-head clinical analysis: MONISTAT DUAL PAK versus MONISTAT DERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MONISTAT DUAL PAK versus MONISTAT DERM.
MONISTAT DUAL- PAK vs MONISTAT-DERM
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Miconazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, reducing ergosterol synthesis and disrupting fungal cell membrane integrity. Tioconazole, also an imidazole, similarly inhibits ergosterol synthesis.
Miconazole inhibits fungal lanosterol 14α-demethylase, a cytochrome P450 enzyme, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Treatment of vulvovaginal candidiasis (yeast infections)
Tinea pedisTinea crurisTinea corporisTinea versicolorCutaneous candidiasis
Intravaginal: One applicatorful of 6.5% miconazole nitrate cream (1200 mg) at bedtime as a single dose. Topical: Apply 2% miconazole nitrate cream to affected area twice daily for 2 weeks.
Topical: Apply once daily to affected areas for 2-4 weeks. Vaginal: One 200 mg suppository at bedtime for 3 days, or one 100 mg suppository at bedtime for 7 days, or one 1200 mg suppository as a single dose.
None Documented
None Documented
The terminal elimination half-life of miconazole following intravenous administration is approximately 24 hours (range 20-30 hours). This supports once-daily dosing for systemic infections, though topical application yields negligible systemic absorption.
Terminal elimination half-life is approximately 24–30 hours, supporting twice-daily or once-daily dosing for dermatologic infections.
Miconazole is primarily metabolized by hepatic CYP3A4; tioconazole undergoes hepatic metabolism, but specific enzymes not fully characterized.
Miconazole is primarily metabolized via oxidative N-dealkylation and aromatic hydroxylation, mainly by CYP3A4 and CYP2C9.
Approximately 90% of an absorbed dose is eliminated in feces as unchanged drug and metabolites; less than 1% is excreted renally as unchanged drug. Biliary excretion is the primary route for the absorbed fraction.
Primarily fecal (biliary) elimination as unchanged drug and metabolites; <1% renal excretion of unchanged drug.
Approximately 88-93% bound to plasma proteins, primarily albumin.
Miconazole is >90% bound to plasma proteins, primarily albumin.
Volume of distribution is approximately 20 L/kg (1400 L for a 70 kg adult), indicating extensive tissue distribution and accumulation in adipose tissues.
Approximately 20 L/kg, indicating extensive tissue distribution (e.g., skin, lungs, liver).
Vaginal absorption: 1.4-5.5% of a 200 mg suppository dose is systemically absorbed. Topical cream: <1% absorbed through intact skin. Oral bioavailability is negligible (<1%) due to poor gastrointestinal absorption.
Topical: Systemic absorption is minimal (<1%), resulting in negligible bioavailability; oral: incomplete (25–30% due to first-pass metabolism), but not used for dermatologic indications.
No dosage adjustment required for renal impairment.
No specific dose adjustment required for topically applied miconazole. For systemic exposure negligible, no GFR-based modifications needed.
No dosage adjustment required for mild to moderate hepatic impairment; use with caution in severe impairment due to limited data.
No specific dose adjustments for topical use. Caution in severe hepatic impairment due to potential systemic absorption from extensive application, but no established guidelines.
Intravaginal use not recommended for prepubertal children. Topical: Apply 2% cream twice daily for 2 weeks for children ≥2 years; safety and efficacy for children <2 years not established.
Children ≥2 years: Apply once daily to affected area for 2-4 weeks. For vaginal use in adolescents: Same as adult dosing.
Same as adult dosing; no specific adjustments required, but consider potential for mucosal irritation and ensure proper administration.
No specific dose adjustment needed. Use caution with extensive application due to thinner skin and potential increased absorption.
None
None.
["Hypersensitivity reactions","Increased risk of bleeding with concurrent warfarin use due to CYP2C9/CYP3A4 inhibition","Monitor for signs of hepatotoxicity","Not for systemic fungal infections"]
Hypersensitivity reactions; avoid occlusive dressings; not for ophthalmic or intravaginal use; potential for hepatotoxicity with systemic absorption.
["Hypersensitivity to miconazole, tioconazole, or any component","Pregnancy (intravaginal application may increase risk of congenital anomalies; use only if clearly needed)"]
Hypersensitivity to miconazole or any component.
Data Pending Review
Data Pending Review
No specific food restrictions. However, alcohol should be avoided during treatment as miconazole may rarely cause a disulfiram-like reaction (nausea, vomiting, flushing).
No clinically significant food interactions. Avoid alcohol if using oral miconazole (not applicable to topical formulation). No dietary restrictions required.
Miconazole is considered low risk during pregnancy. No increased risk of malformations or adverse fetal outcomes has been reported in epidemiologic studies for topical/vaginal use. First trimester: data limited but no clear teratogenic signal. Second and third trimesters: generally considered safe; systemic absorption from vaginal use is minimal (<2%). Category C (pre-2015 FDA).
In pregnancy category C. Systemic absorption is minimal; however, use in the first trimester is avoided unless clearly necessary. No evidence of teratogenicity in animal studies with topical application.
Miconazole is poorly absorbed systemically after vaginal administration. Excretion into breast milk is negligible. The M/P ratio is not determined due to minimal systemic absorption. Compatible with breastfeeding; wash hands after application to avoid infant contact.
Excretion into human milk is unknown. M/P ratio not established. Consider relevance of maternal dose (topical application with minimal systemic absorption). Use with caution.
No dose adjustment is necessary for vaginal miconazole during pregnancy. Pharmacokinetics of topical/vaginal miconazole are not significantly altered in pregnancy due to minimal systemic absorption. Standard dosing: one suppository (1200 mg) as a single dose or 200 mg intravaginally at bedtime for 3 or 7 days depending on formulation.
No dose adjustment required. Pharmacokinetics of topical miconazole are not significantly altered in pregnancy.
Category C
Category C
MONISTAT DUAL-PAK contains miconazole nitrate (vaginal suppository) and miconazole nitrate cream (external). Treatment is 1 suppository at bedtime for 3 or 7 days depending on package. Advise patient to complete full course even if symptoms improve. Do not use tampons, douches, or spermicides during treatment. Discontinue if abdominal pain, fever, or foul-smelling discharge occur. Not for use during pregnancy unless directed by a physician.
MONISTAT-DERM (miconazole nitrate) is a broad-spectrum antifungal effective against dermatophytes and Candida. For tinea pedis, treat for 4 weeks to prevent recurrence. Avoid occlusion unless directed, as it may increase irritation. In intertriginous areas, apply sparingly to prevent maceration. Combination with low-potency corticosteroid may reduce inflammation in severe cases, but monotherapy is preferred.
Use the vaginal suppository at bedtime for the recommended number of nights (3 or 7).Apply the external cream to the vulvar area twice daily as needed for itching and irritation.Do not use tampons, douches, or vaginal sex during treatment.Wear a panty liner or pad to protect clothing from leakage.Complete the full course even if symptoms resolve to prevent recurrence.If symptoms persist beyond 7 days or recur within 2 months, consult a healthcare provider.Do not use if you are pregnant or breastfeeding without medical advice.Avoid alcohol consumption during treatment as miconazole may cause disulfiram-like reaction (rare).
Apply the cream to the affected area and surrounding skin twice daily (morning and evening).Wash hands before and after application; do not use in eyes or ingest.Continue use for the full prescribed duration (e.g., 2 weeks for tinea cruris, 4 weeks for tinea pedis) even if symptoms improve.Avoid sharing towels or clothing to prevent reinfection.Notify your doctor if rash worsens or if burning, blistering, or discharge occurs.